The caudal (Cdx) family of DNA binding proteins was originally identified in Drosophila; however, homologues with conserved molecular structure and function have been described in several organisms including humans. There are three members in the Cdx family in mice and humans, including Cdx1, Cdx2, and Cdx4. The role in axial elongation and early antero-posterior patterning has been intensively studied. Cdx1 and Cdx2 regulate cell growth and differentiation, and they are involved in embryonic development of the intestinal tract, intestinal inflammation and tumorigenesis. In colon cancer, CDX1 and CDX2 suppress colon cell proliferation, migration and invasion by inhibiting β-catenin/TCF transcriptional activity. The expression of CDX1 and CDX2 exists in intestinal metaplasia but not in normal gastric and esophageal mucosa. CDX genes are overexpressed in leukemias. The changes in expression levels of Cdx genes correlate with oncogenic transformation. CDX2 serves as a Wnt signaling inhibitor and is frequently methylated in lung cancer. CDX2 methylation is also a feature of human esophageal squamous cancer, and it may serve as a cancer detection marker.
Introduction
It is estimated that the human genome contains ≥ 200 homeobox genes [1] . Homeobox-containing genes constitute a gene family characterized by a highly conserved 183-nucleotide sequence encoding a 61 amino acid domain, which is referred to as the homeodomain (HD) [2] . Homeobox genes are divided into 2 classes. Class I includes clustered genes (HOX) comprised of 39 members, and the class II homeobox genes are distributed to the whole genome, including the MSX, ParaHox, PAX, DLX, and Engrailed (EN) small families [3] . The ParaHox family of homeobox genes includes the Cdx, Gsx and Pdx genes [4] . The Cdx (caudal-type homeobox) gene family encodes homeodomain transcription factors. The human genome contains three Cdx genes (CDX1, CDX2 and CDX4). The aberrant expression of these genes is associated with intestinal metaplasias and tumors [5, 6] .
Aberrant genetic and expression changes in CDX1 and CDX2 during Colon Cancer initiation and progression
CDX1 is reported to be both a tumor suppressor and an oncogene in human colon cancer. It is involved in cell transformation and tumorigenesis in intestinal epithelial cells [7] . Human CDX1 is located at 5q32, a fragile site in colorectal cancer. CDX1 was down-regulated by p53 in non-transformed intestinal IEC-6 cells and the SW480 colon cancer cell line [8] . Reduction or loss of CDX1 expression was reported in a majority of colon cancers [9, 10] . Loss or reduction of CDX1 expression is due to promoter region hypermethylation rather than mutation in the coding region REVIEW [11] [12] [13] . Pilozzi et al. reported that reduced expression of CDX1 was found in 7 of 19 cases of colorectal cancer [14] . CDX1 is upregulated by APC/β-catenin and Ras during embryonic intestine development and colon tumor initiation and progression [15] [16] [17] .
Human CDX2 is localized to chromosome 13q12.3. Previous studies found that mutations in CDX2 are rare in human colorectal cancers, except for a loss of heterozygosity, which was found in approximately 10% of colorectal cancers (CRCs) [18] . Lorentz et al. showed that activation of the Protein Kinase C (PKC) pathway by RAS is responsible for the down-regulation of CDX2 expression in human colonic Caco-2 and HT-29 cells [16] . In heterozygous Cdx2 mice, reduced expression of CDX2 resulted in chromosomal instability mediated by the mTOR pathway [19] .
The function of CDX1 and CDX2 in colon cancer
CDX1 and CDX2 suppress colon cell proliferation, migration and invasion. CDX1 inhibits the proliferation of colon cells by inhibiting β-catenin/TCF transcriptional activity [20, 21] . CDX2 binds to β-catenin and disrupts its interaction with DNA-binding TCF factors, thereby silencing β-catenin/TCF target gene expression [22] . Brabletz et al. found that the expression of CDX2 was transiently down-regulated in tumorigenicity in colorectal cancer and re-expressed in metastases [23, 24] . Olsen et al. reported that CDX2 regulated the Wnt/β-catenin signaling pathway by binding to AXIN2 and APC promoter region [24] . Coskun et al. revealed that tumor necrosis factor-α (TNF-α) suppressed CDX2 expression to activate Wnt signaling by NF-κB and p38 MAPK pathway in Caco-2 cells [25] . CDX2 has also been found to block cell-cycle progression in a non-transcriptional manner by stabilizing p27
Kip1 protein and inhibiting cell proliferation [26] . Renouf et al. reported that CDX2 acted as a DNA repair inhibitor, a novel function for CDX2. This mechanism is based on the interaction of CDX2 with Ku70/80 proteins and subsequent inhibition of the non-homologous end joining (NHEJ) DNA repair machinery [27] . CDX1 and CDX2 hamper cell migration and invasion, thereby suppressing the epithelial-mesenchymal transition (EMT) process. Loss of Cdx2 or Cdx1-Cdx2 in APC Min/+ background mice resulted in the loss of expression of the epithelial marker E-cadherin and a gain in expression of vimentin, Twist1, Zeb1, and Zeb2 [28] . In Colo 205 cells, CDX1 or CDX2 reduced β-and p120-catenin tyrosine phosphorylation and restored E-cadherin-mediated cell adhesion [29] . Gross et al. also reported that CDX2 retarded wound repair and migration [30] .
Epigenetic regulation of the Cdx family
NF-κB signaling is able to transcriptionally activate CDX1 expression by directly binding to its unmethylated promoter. In normal gastric mucosa, CDX1 is not expressed due to high levels of methylation in its promoter region. The methylation level of the CDX1 promoter decreases during helicobacter pylori gastritis and intestinal metaplasia, and it reaches the lowest level in low-grade intraepithelial neoplasia of the stomach. NF-κB binding to the CDX1 promoter is impaired by its methylation [31] . Tahara et al. observed the methylation status of CDX1 by performing bisulfite pyrosequencing in ulcerative colitis (UC). An association was found between CDX1 methylation and severe UC phenotypes [32] . Downregulation of CDX2 expression by promoter region methylation was frequently found in human colorectal cancer [33] . Silencing of CDX2 expression by promoter region hypermethylation was reported in human esophageal and lung cancer. CDX2 methylation is a feature more commonly associated with human esophageal squamous carcinoma than adenocarcinoma [34, 35] .
CDX Expression in intestinal metaplasia of the stomach
Intestinal metaplasia (IM) is a preneoplastic lesion of the stomach in which the normal gastric mucosa is replaced by mucosa that resembles intestine [36, 37] . IM is part of a stepwise sequence of alterations in the gastric mucosa that ultimately leads to gastric cancer [36, 38] . CDX1 and CDX2 are expressed in the epithelium of the small intestine and colon, where they play an important role in regulating cell proliferation and differentiation [6, 39] . Almeida et al. reported that CDX1 staining was detected in all foci of IM and in 41% of gastric carcinomas, while CDX2 expression was observed in 17/18 foci of IM and in 54% of gastric carcinomas by immunohistochemistry [36] . CDX1-induced SALL4 and KLF5 converted gastric epithelial cells into tissue stem-like progenitor cells, which transdifferentiated into intestinal epithelial cells [40] . Liu et al. reported that CDX2 expression was progressively reduced in incomplete IM, gastric dysplasia and cancer. Meanwhile, CDX2 expression was also inversely correlated with the expression of MUC5 and MUC6 in gastric cancer, supporting the tumor suppressive role of CDX2 in IM [41] .
CDX Expression in Barrett's esophagus
Barrett's esophagus (BE) is a premalignant condition of the distal esophagus that is associated with a high risk of esophageal cancer [42] . CDX1 and CDX2 play an important role in the development of Barrett's esophagus. Eda et al. reported that CDX1/2 expression was not detected in normal esophageal mucosa. The level of CDX1/2 mRNA expression was significantly higher in the mucosa from patients with Barrett's epithelium compared to the mucosa from patients without Barrett's epithelium [43] . CDX-2 nuclear staining was found in 87.5% of the BE biopsies, whereas normal squamous esophagus and cardia biopsies were negative [44] . CDX2 expression was observed in all cases of Barrett's epithelium. CDX2 acts as a sensitive marker of intestinal metaplasia in the esophagus and is useful in detecting histologically equivocal cases of Barrett's esophagus [45] .
Ectopic expression of the CDX gene family in leukemia
CDX2 and CDX4 are key regulators in embryonic hematopoietic development. Aberrant expression of CDX2 is a frequent event in acute leukemia, and CDX4 is expressed in a minority of patients [3] . CDX2 leads to dysregulation of Hox genes, including upregulation of Hoxb8 and downregulation of Hoxa10 [46] . Aberrant expression of CDX2 in hematopoietic stem and progenitor cells causes silencing of KLF4, which in turn leads to upregulation of PPARγ signaling intermediates, thereby sensitizing leukemic cells to PPARγ agonist treatment [47] . CDX2 is expressed in 90% of AML (acute myeloid leukemia) patients, but it is not expressed in hematopoietic stem and progenitor cells from normal individuals. Aberrant expression of CDX2 promotes the proliferation and self-renewal potential of myeloid progenitor cells [48] . CDX2 is aberrantly expressed in 81% of adult ALL (acute lymphoblastic leukemia), predicting poor treatment outcome in patients. High level expression of CDX2 was correlated with the ALL subtype pro-B ALL, Ph + ALL and early T-ALL [49] . In pediatric ALL, high level expression of CDX2 correlates with persistence of minimal residual disease (MRD) during the course of treatment. Thus, the expression of CDX2 serves as a marker for adverse prognosis [50] . Bansal et al. reported that CDX4 was aberrantly expressed in 25% of AML patient samples. In addition, CDX4 participates in MLL-AF9-mediated leukemogenesis [51] .
Conclusion
Members of the caudal gene family (Cdx1, Cdx2 and Cdx4) play essential roles in embryonic development. Cdx1 and Cdx2, but not Cdx4, participate in intestinal epithelial proliferation, differentiation and the regulation of intestine specific genes. CDX1 and CDX2 act as tumor suppressors and oncogenes in CRC. Ectopic expression of CDX1 and CDX2 induce gastric intestinal metaplasia and Barrett's esophagus. In addition, they may serve as predictive markers for a higher risk of gastric and esophageal cancers. CDX2 is aberrantly expressed in adult ALL, predicting poor treatment outcome in patients.
